Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial
M. Parellada, A. San José Cáceres, R. Delorme, A. Moscoso et autres
Background: Previous trials have indicated the potential of arbaclofen for improving social difficulties among autistic children and adolescents with fluent speech. AIMS-2-TRIALS-Clinical Trial 1 (AIMS-2-CT1) examined whether arbaclofen is superior to placebo in improving social function and other secondary outcomes, along with …
es, fr, gb, pl, us, nl (code pays fourni par la source)
2 citations
EClinicalMedicine